4.6 Article

Hospitalization cost of Pressurized Intraperitoneal Aerosol chemotherapy (PIPAC)

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study

Vahan Kepenekian et al.

Summary: For initially non-resectable DMPM patients, pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant treatment approach is feasible and may facilitate complete secondary resection.

ANNALS OF SURGICAL ONCOLOGY (2022)

Article Oncology

Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with gastric cancer and peritoneal metastasis

Mehdi Javanbakht et al.

Summary: This study assessed the cost-effectiveness of pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) for the treatment of advanced gastric cancer. The results showed that PIPAC C/D plus chemotherapy is a cost-effective strategy for upfront therapy, and PIPAC C/D as a second-line therapy has the potential to reduce costs and improve clinical outcomes for patients with advanced gastric cancer.
Article Gastroenterology & Hepatology

Assessment of postoperative pain after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of peritoneal metastasis

Fatah Tidadini et al.

Summary: This study aimed to assess postoperative pain and morbidity in patients undergoing pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis (PM). The results showed that PIPAC was well-tolerated and pain was well-controlled in the majority of patients. Oxaliplatin was associated with greater pain, and moderate-to-severe pain was associated with longer hospital stays.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2022)

Article Oncology

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer

Mohammad Alyami et al.

Summary: The study showed that PIPAC with low-dose cisplatin and doxorubicin in combination with systemic chemotherapy is safe and feasible for patients with unresectable PM from gastric origin. The survival data are encouraging and support further clinical studies in this indication.
Article Oncology

PIPAC versus HIPEC: cisplatin spatial distribution and diffusion in a swine model

Axel Davigo et al.

INTERNATIONAL JOURNAL OF HYPERTHERMIA (2020)

Article Gastroenterology & Hepatology

Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Carcinomatosis: A Retrospective Cohort Study

Martin Huebner et al.

GASTROENTEROLOGY RESEARCH AND PRACTICE (2017)

Article Gastroenterology & Hepatology

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis

Giorgi Nadiradze et al.

JOURNAL OF GASTROINTESTINAL SURGERY (2016)

Article Gastroenterology & Hepatology

Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis

C. Demtroeder et al.

COLORECTAL DISEASE (2016)

Article Surgery

Description of a novel approach for intraperitoneal drug delivery and the related device

Wiebke Solass et al.

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2012)